Use of biomarkers in the detection of early and preclinical Alzheimer's disease (AD) has become of central importance for the diagnosis of AD, mild cognitive impairment (MCI), and preclinical AD following publication of the NIA-Alzheimer's Association revised criteria for diagnosis
across the spectrum of AD pathogenesis. The use of in vivo PET amyloid imaging agents, such as
, allows early detection of AD pathological processes and subsequent neurodegeneration. Imaging with PiB provides early, or perhaps even preclinical,
detection of disease and accurately distinguishes AD from dementias of other etiologies in which the diagnostic distinction is difficult to make clinically. From a research perspective, utilizing amyloid imaging agents allows us to study relationships between amyloid pathology and changes
in cognition, brain structure, and function across the continuum from normal aging to MCI to AD. The present review focuses on use of PiB-PET across the spectrum of AD pathogenesis.
No Supplementary Data.
No Article Media
PITTSBURGH COMPOUND B
Document Type: Research Article
May 1, 2016
More about this publication?
Technology and Innovation, edited and published by the National Academy of Inventors, is a forum for presenting information encompassing the entire field of applied sciences, with a focus on transformative technology and academic innovation. Regular features of T&I include commentaries contributed by the United States Patent and Trademark Office (USPTO) and in-depth profiles of Fellows of the National Academy of Inventors in every issue.